Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel (D) subgroup.

被引：0
|
作者：
Cislo, Paul
Reuning-Scherer, Jonathan D.
机构：
[1] Bayer HealthCare, Whippany, NJ USA
[2] Yale Univ, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.254
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
254
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel (D) therapy in the phase 3 ALSYMPCA trial
    Koenig, F.
    Vogelzang, N. J.
    Helle, S., I
    Johannessen, D. C.
    O'Sullivan, J. M.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Shan, M.
    Parker, C.
    ONKOLOGIE, 2013, 36 : 78 - 78
  • [22] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel in the phase 3 ALSYMPCA trial
    Koenig, F.
    Vogelzang, N. J.
    Helle, S. I.
    Johannessen, D. C.
    O'Sullivan, J. M.
    Garcia-Vargas, J.
    Tear, C. G. O'Bryan
    Shan, M.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [23] Single-Institution Experience With Radium-223 Dichloride (Ra-223) for Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Cox, B. W.
    Wang, L.
    Bradley, T.
    Gu, B.
    Kelley, K.
    Potters, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S470 - S470
  • [24] Patient-reported quality of life (QOL) after radium-223 dichloride (Ra-223) treatment within the phase 3 ALSYMPCA study- an anaylsis with respect to pain relief
    Heinzer, H.
    Nilsson, S.
    Tomblyn, M.
    Cislo, P.
    Reuning-Scherer, J.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 179 - 179
  • [25] Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases.
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group
    Wedel, S.
    Wiechno, P.
    Helle, S., I
    Logue, J.
    Nilsson, S.
    Sartor, O.
    Coleman, R. E.
    Kliment, J.
    Fang, F.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 86 - 87
  • [27] Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group
    Wiechno, P.
    Helle, S. I.
    Logue, J.
    Nilsson, S.
    Sartor, O.
    Coleman, R. E.
    Kliment, J.
    Fang, F.
    Parker, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S690 - S691
  • [28] Treatment Patterns, Patient Characteristics, and Preliminary Safety in the Radium-223 (Ra-223) REASSURE Observational Study
    Zimberg, S. H.
    Richardson, T.
    Sylvester, J. E.
    Given, R.
    Kipper, M.
    Mantz, C.
    Morris, D.
    Perlmutter, M.
    Song, D.
    Fernandez, E.
    Brookland, R. K.
    Tchekmedyian, N.
    Hafron, J.
    Hartford, A. C.
    Peddada, A. V.
    Vacirca, J.
    De Sanctis, Y.
    Muenz-Wollny, R.
    Conti, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E281 - E282
  • [29] PAIN AND QUALITY OF LIFE (QOL) ANALYSES FROM THE PHASE 3 RANDOMIZED ALSYMPCA STUDY WITH RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS WITH BONE METASTASES
    Tomblyn, Michael
    Nilsson, Sten
    Vogelzang, Nicholas
    Sartor, A. Oliver
    Cislo, Paul
    Van Gool, Renilt
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF UROLOGY, 2013, 189 (04): : E293 - E293
  • [30] 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Amadori, D.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Vogelzang, N. J.
    Sartor, A.
    Coleman, R. E.
    Govi, S.
    Fang, F.
    Skjorestad, I.
    Nilsson, S.
    Parker, C.
    ANNALS OF ONCOLOGY, 2015, 26 : 55 - 55
12345